placebo in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Cov-2067 Weinreich (1200mg) Cohort 1, 2020 (REV) 2.25 [0.26; 19.26]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 (REV) 0.99 [0.02; 50.39]
1.86 [0.28 ; 12.26 ] Cov-2067 Weinreich (1200mg) Cohort 1, 2020 (REV), Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 (REV) 2 0% 2,981 moderate not evaluable hospitalization or deathdetailed results Cov-2067 Weinreich (1200mg) Cohort 1, 2020 (REV) 3.45 [1.48; 8.06]
3.45 [1.48 ; 8.06 ] Cov-2067 Weinreich (1200mg) Cohort 1, 2020 (REV) 1 0% 1,484 NA not evaluable hospitalizationdetailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 (REV) 12.18 [0.67; 221.09]
12.18 [0.67 ; 221.09 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 (REV) 1 0% 204 NA not evaluable symptomatic Covid-19detailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 (REV) 1.80 [1.00; 3.21]
1.80 [1.00 ; 3.21 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 (REV) 1 0% 204 NA not evaluable serious adverse eventsdetailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 (REV) 4.05 [0.45; 36.68]
4.05 [0.45 ; 36.68 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 (REV) 1 0% 311 NA not evaluable adverse eventsdetailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 (REV) 1.83 [1.16; 2.90]
1.83 [1.16 ; 2.90 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 (REV) 1 0% 311 NA not evaluable 0.5 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-27 17:22 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
